Product Overview

AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.

Neurology & Metabolic Disorders

Adasuve®

Adasuve® is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. 

Drug Facts
Active Ingredient
Loxapine
Neurology & Metabolic Disorders

Dystardis®

Dystardis® is indicated for the treatment of moderate to severe late dyskinesia. Late dyskinesia is a disorder characterized by uncontrollable movements such as cramping in the stomach Face, making faces, or abnormal tongue movements.

Drug Facts
Active Ingredient
Tetrabenazine
Neurology & Metabolic Disorders

Feraccru®

Feraccru® is indicated for adults for the treatment of iron deficiency.

Drug Facts
Active Ingredient
Ferric-maltol
Neurology & Metabolic Disorders

Ospolot®

Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.

Drug Facts
Active Ingredient
Sultiame
Neurology & Metabolic Disorders

Tetmodis®

Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologies such as tardive dyskinesia, tics and dystonia.

Drug Facts
Active Ingredient
Tetrabenazine
Neurology & Metabolic Disorders

Wakix®

Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.

Drug Facts
Active Ingredient
Pitolisant